Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson's
Why Is Gain Therapeutics (GANX) Stock Moving Today?
Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock
Profile – Matthias Alder, Gain Therapeutics
Gain Therapeutics - Force Family Office
Gain Therapeutics Inc (GANX) Stock Message Board
Gain Therapeutics raised $46 million through Nasdaq listing
Gain Therapeutics (@GainThera) / X
What Kind Of Investors Own Most Of Gain Therapeutics, Inc. (NASDAQ
Home Perspectives from Gain Therapeutics
Gain Therapeutics
Gain Therapeutics, Inc.
Gain Therapeutics presents hopeful data for Parkinson's, Gaucher
Gain Therapeutics Benzinga Healthcare Small Cap Conference
Gain Therapeutics' Small Molecule Approach for CNS Diseases
